“…In this issue’s first review, Alber et al elaborated on exciting updates in the field of critical care. 4 The authors discussed how the European Society of Intensive Care Medicine and American Thoracic Society updated management guidelines for ARDS with many important lessons learned from the COVID-19 pandemic. 5,6 In two potentially practice-changing randomized controlled trials (RCTs) included in this review, hydrocortisone improved 28-day mortality in severe community-acquired pneumonia, 7 and preventive inhaled amikacin decreased the rate of ventilator-associated pneumonia at 28 days.…”